Skip to content

Clinical Efficacy and Safety of Warm Acupuncture in the treatment of Type 2 Diabetic Kidney Disease: A protocol of a randomized controlled trial

Clinical Efficacy and Safety of Warm Acupuncture in the treatment of Type 2 Diabetic Kidney Disease: A protocol of a randomized controlled trial

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20221104004
Enrollment
84
Registered
2022-11-04
Start date
2022-11-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic kidney disease (DKD) is one of the most common and harmful chronic complications in clinical practice, and there is no reliable and targeted treatment plan at present. As a classic complementary and alternative therapy, evidence have shown that warm acupuncture has advantages in the treatment of type 2 DKD. However, there is still a lack of high-quality and long-term follow-up randomized controlled trials (RCTs) of warm acupuncture in the treatment of type 2 DKD. Warm acupunctur

Interventions

The patients who meet the criteria will be randomly divided into the treatment group and the control group. According to the recommendations of clinical guidelines, the two groups of patients will be
Experimental Other
warm acupuncture

Sponsors

Hongbo Chen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1 Meet the diagnostic criteria of type 2 DKD 2 Age no less than 18 years old, and be not more than 70 years old, regardless of gender 3With the 24-hour urinary protein quantification was 0.5-3.5 g 4 With serum creatinine less than 265umol/L 5 Patients voluntarily participated in the trial and signed informed consent

Exclusion criteria

Exclusion criteria: (1) Nephropathy due to hypertension or other diseases; (2) Complicated with severe complications and other serious organ dysfunction; (3)Complicated with severe heart disease (NYHA class 3 or above, severe arrhythmia), abnormal liver function (alanine aminotransferase, aspartate aminotransferase no less than 1.5 times the upper limit of normal value), hematopoietic system diseases (moderate to severe anemia); (4) Complicated with severe infection, diabetic ketoacidosis, hyperkalemia; (5) Complicated with severe mental illness; (6) Pregnant or lactating women; (7) Patients with a history of allergy to one of the drugs used in the study; (8) Subjects participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
24-hour urinary protein 8, 12, and 24 weeks urinalysis test

Secondary

MeasureTime frame
Renal function 8, 12, and 24 weeks Renal function test

Countries

China

Contacts

Public ContactYuancheng Gao

The First Affiliated Hospital of Zhejiang Chinese Medical University

mimashi@126.com18955753374

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026